Prescriptions for popular weight-loss medications have plunged by 84 per cent in four US states following the withdrawal of Medicaid coverage, exposing the impact of insurance policies on access to obesity treatment.
The decline followed a January 1, 2026 decision by California, New Hampshire, Pennsylvania and South Carolina to discontinue Medicaid coverage for GLP-1 medications approved for weight management, citing their high costs, Newsweek reported.
A study published in the Journal of the American Medical Association (JAMA) found that quarterly prescriptions in the four states dropped from 2,914 to 421 per 100,000 Medicaid beneficiaries between the final quarter of 2025 and the first quarter of 2026.
By comparison, prescriptions in 10 states that retained coverage recorded a smaller decline, falling from 3,006 to 2,758 over the same period.
The study’s lead author, Bryant Shuey, an assistant professor of medicine at the University of Pittsburgh, warned that discontinuing the medications could result in weight regain and worsening cardiometabolic risk factors. He cited clinical trial findings showing that 82 per cent of participants who stopped tirzepatide regained some of the weight they had previously lost.
The researchers estimated that the coverage withdrawals could have resulted in between 175,500 and 526,600 fewer Medicaid beneficiaries filling prescriptions for weight-loss GLP-1 drugs across the four states. However, they noted that the research measured prescription records rather than individual patients and could not establish how many people completely discontinued treatment.

